HighVista Strategies LLC Invests $737,000 in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

HighVista Strategies LLC purchased a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA) in the third quarter, HoldingsChannel reports. The firm purchased 46,116 shares of the company’s stock, valued at approximately $737,000.

Several other institutional investors have also made changes to their positions in CNTA. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC raised its position in Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares in the last quarter. Quarry LP lifted its position in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after buying an additional 3,108 shares during the last quarter. Sandia Investment Management LP bought a new position in shares of Centessa Pharmaceuticals in the second quarter worth about $90,000. Finally, Fred Alger Management LLC bought a new position in Centessa Pharmaceuticals in the 2nd quarter valued at approximately $99,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Stock Down 5.4 %

Shares of CNTA opened at $16.95 on Tuesday. Centessa Pharmaceuticals plc has a 52 week low of $6.15 and a 52 week high of $18.74. The stock has a 50 day moving average price of $16.22 and a two-hundred day moving average price of $12.72. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05. On average, analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Wall Street Analyst Weigh In

CNTA has been the topic of several recent research reports. Oppenheimer reiterated an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Guggenheim increased their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 15th. BMO Capital Markets raised their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Jefferies Financial Group increased their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Finally, B. Riley started coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $25.83.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $17.66, for a total transaction of $176,600.00. Following the completion of the sale, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $3,236,477.56. This trade represents a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $16.53, for a total value of $909,150.00. Following the completion of the transaction, the chief executive officer now directly owns 721,924 shares in the company, valued at approximately $11,933,403.72. This represents a 7.08 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 375,128 shares of company stock worth $6,148,522 in the last quarter. 11.59% of the stock is currently owned by corporate insiders.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.